May 30, 2016 8:53 PM ET

Biotechnology

Company Overview of Alnylam Pharmaceuticals, Inc.

Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the trea...

300 Third Street

3rd Floor

Cambridge, MA 02142

United States

Founded in 2002

369 Employees

Phone:

617-551-8200

Fax:

617-551-8101

Key Executives for Alnylam Pharmaceuticals, Inc.

Chief Executive Officer and Executive Director
Age: 52
Total Annual Compensation: $710.3K
President and Chief Operating Officer
Age: 52
Total Annual Compensation: $530.5K
Vice President of Finance and Treasurer
Age: 40
Total Annual Compensation: $300.0K
Chief Medical Officer and Executive Vice President of Research & Development
Age: 52
Total Annual Compensation: $500.1K
Chief Business Officer and Senior Vice President
Age: 43
Total Annual Compensation: $441.1K
Compensation as of Fiscal Year 2015.

Alnylam Pharmaceuticals, Inc. Key Developments

Alnylam Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Provides Revenue Guidance for the Year 2016

Alnylam Pharmaceuticals announced unaudited consolidated earnings results for the first quarter ended March 31, 2016. For the quarter, the company announced GAAP net loss was $103 million or $1.21 on both a basic and diluted basis, including $23.5 million of non-cash stock-based compensation expense as compared to a net loss of $50.8 million or $0.62 per share on both a basic and diluted basis, including $8.2 million of non-cash stock-based compensation expense for the same period in the previous year. Revenues were $7.3 million for the first quarter of 2016 as compared to $18.5 million for the same period last year. Revenues for the first quarter of 2016 included $4.4 million from the company’s alliance with Sanofi-Genzyme, $2.7 million from its alliance with The Medicines Company and $0.2 million from other sources. A decrease in revenues in the quarter ended March 31, 2016, compared to the prior period was due primarily to the completion of the company's performance obligation under the Monsanto agreement in February 2015 and the completion of its revenue amortization under the Takeda agreement in May 2015, partially offset by higher revenue from its agreement with Sanofi-Genzyme. Loss before income taxes was $102.974 million compared to $51.208 million a year ago. The decrease in revenues in the quarter ended March 31, 2016 as compared to the prior year period was due primarily to the completion of the company’s performance obligations under the Monsanto agreement in February 2015 and the completion of its revenue amortization under the Takeda agreement in May 2015, partially offset by higher revenue from its agreement with Sanofi Genzyme. The company expects net revenues from collaborators to increase during the remainder of 2016 due to expected increases in expense reimbursement and an expected milestone payment under its agreement with Sanofi Genzyme.

Alnylam Pharmaceuticals, Inc. to Break Ground on New Manufacturing Facility in Norton, Massachusetts

Alnylam Pharmaceuticals, Inc. announced that it will break ground on a biopharmaceutical manufacturing facility in Norton, Massachusetts. The facility will supply RNAi therapeutics for Alnylam's clinical and commercial needs. The location, selected in close collaboration with Commonwealth and local officials, demonstrates Alnylam's ongoing commitment to Massachusetts. Construction on the 200,000 square foot manufacturing facility is expected to complete in 2018 and it will initially employ approximately 150 new full-time employees.

Alnylam Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-12-2016 10:00 AM

Alnylam Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2016 Healthcare Conference, May-12-2016 10:00 AM. Venue: The Encore at Wynn, 3131 S Las Vegas Blvd, Las Vegas, NV 89109, United States. Speakers: John M. Maraganore, Chief Executive Officer and Executive Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States
3D Biomatrix Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alnylam Pharmaceuticals, Inc., please visit www.alnylam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.